HNC: Human Neural Circuits Electrophysiology During Cognition

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT05962424
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Psychiatric Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ketamine Hydrochloride — DRUG
    Ketamine is an FDA-approved dissociative anesthetic.

Study Details

The purpose of this study is to understand how ketamine brings about dissociative symptoms.

Key Dates

Start date
Oct 5, 2023
Status verified
Apr 2026
Primary completion
Sep 1, 2030
Completion
Sep 1, 2030

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Ketamine
    Study participants will receive 0.5mg/kg of ketamine - one single infusion

Primary Outcome Measure

Number of participants with dissociative events during ketamine infusion as assessed by CADSS (Clinician-Administered Dissociative State Scale) [ Time Frame: up to 1 week ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford UniversityPalo AltoCalifornia94306
Kishandra Patron, BS

Find similar trials in Palo Alto, CA

By research site
Stanford University· Palo Alto, CA

Related Studies